These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 39110673)

  • 1. Comparative analysis of novel hormonal agents in non-metastatic castration-resistant prostate cancer: A Taiwanese perspective.
    Huang PC; Huang LH; Yang CK; Li JR; Chen CS; Wang SS; Chiu KY; Ou YC; Lin CY
    PLoS One; 2024; 19(8):e0306900. PubMed ID: 39110673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States.
    Hussain A; Jiang S; Varghese D; Appukkuttan S; Kebede N; Gnanasakthy K; Macahilig C; Waldeck R; Corman S
    BMC Cancer; 2022 Mar; 22(1):304. PubMed ID: 35317768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Mori K; Mostafaei H; Pradere B; Motlagh RS; Quhal F; Laukhtina E; Schuettfort VM; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF
    Int J Clin Oncol; 2020 Nov; 25(11):1892-1900. PubMed ID: 32924096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study.
    Hara S; Mori K; Fukuokaya W; Tomomasa N; Oguchi T; Takahashi Y; Saito S; Katami J; Sano T; Kadena S; Hashimoto M; Yata Y; Nishi E; Suhara Y; Takamizawa S; Kurawaki S; Suzuki H; Miyajima K; Iwatani K; Urabe F; Ito K; Yanagisawa T; Tsuzuki S; Shimomura T; Kimura T
    Int J Clin Oncol; 2024 Aug; 29(8):1191-1197. PubMed ID: 38769191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
    Kumar J; Jazayeri SB; Gautam S; Norez D; Alam MU; Tanneru K; Bazargani S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
    Urol Oncol; 2020 Nov; 38(11):826-834. PubMed ID: 32605736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer.
    Appukkuttan S; Farej R; Miles L; Purser M; Wen L
    J Manag Care Spec Pharm; 2021 Feb; 27(2):166-174. PubMed ID: 33141615
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment and trials in non-metastatic castration-resistant prostate cancer.
    Lokeshwar SD; Klaassen Z; Saad F
    Nat Rev Urol; 2021 Jul; 18(7):433-442. PubMed ID: 34002069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Wenzel M; Nocera L; Collà Ruvolo C; Würnschimmel C; Tian Z; Shariat SF; Saad F; Tilki D; Graefen M; Kluth LA; Briganti A; Mandel P; Montorsi F; Chun FKH; Karakiewicz PI
    Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):139-148. PubMed ID: 34054128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    Halabi S; Jiang S; Terasawa E; Garcia-Horton V; Ayyagari R; Waldeck AR; Shore N
    J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer.
    Swami U; Agarwal N
    Cancer Treat Res Commun; 2020; 25():100205. PubMed ID: 32822968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison.
    Shore N; Jiang S; Garcia-Horton V; Terasawa E; Steffen D; Chin A; Ayyagari R; Partridge J; Waldeck AR
    Adv Ther; 2022 Nov; 39(11):5025-5042. PubMed ID: 36028656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors.
    Appukkuttan S; Ko G; Fu C; Bannister B; Kong SX; Jhaveri J; Freedland SJ
    Expert Rev Anticancer Ther; 2024 May; 24(5):325-333. PubMed ID: 38469875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents.
    Rizzo A; Oderda M; Mollica V; Merler S; Morelli F; Fragomeno B; Taveri E; Sorgentoni G; Santoni M; Massari F
    Anticancer Drugs; 2022 Jan; 33(1):e43-e51. PubMed ID: 34387593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
    Esther J; Maughan BL; Anderson N; Agarwal N; Hahn AW
    Curr Treat Options Oncol; 2019 Feb; 20(2):14. PubMed ID: 30741354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide.
    Wallis CJD; Chandrasekar T; Goldberg H; Klotz L; Fleshner N; Satkunasivam R; Klaassen Z
    Eur Urol Oncol; 2018 Aug; 1(3):238-241. PubMed ID: 31102627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential therapy with darolutamide in patients with non-metastatic castration-resistant prostate cancer resistant to enzalutamide or apalutamide.
    Fujmoto S; Fujita K; Nishimoto M; Hamaguchi M; Kuwahara K; Hashimoto M; Adomi S; Minami T; Nozawa M; Yoshimura K; Uemura H
    Cancer Med; 2023 Feb; 12(3):3176-3179. PubMed ID: 36043427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
    Smith MR; Antonarakis ES; Ryan CJ; Berry WR; Shore ND; Liu G; Alumkal JJ; Higano CS; Chow Maneval E; Bandekar R; de Boer CJ; Yu MK; Rathkopf DE
    Eur Urol; 2016 Dec; 70(6):963-970. PubMed ID: 27160947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan.
    Fujiwara M; Yuasa T; Komai Y; Numao N; Yamamoto S; Fukui I; Yonese J
    Target Oncol; 2020 Oct; 15(5):635-643. PubMed ID: 33037973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Ladouceur M; Behl AS; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
    Adv Ther; 2020 Jan; 37(1):501-511. PubMed ID: 31813086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Darolutamide in hormone-sensitive and castration-resistant prostate cancer.
    Palmieri VE; Roviello G; D'Angelo A; Casadei C; De Giorgi U; Giorgione R
    Expert Rev Clin Pharmacol; 2021 May; 14(5):535-544. PubMed ID: 33685318
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.